Clinical Studies

Description

Rapamycin has an immunosuppressive that has significant anticancer activity. It has been approved for use in several human cancer indications. Anecdotal reports of Rapamycin activity in canine hemangiosarcoma have been made over several years, however its activity has been unpredictable.

Recent genomic analysis of hemangiosarcoma in dogs provides a scientific basis for this sporadic activity based on the existence of hemangiosarcoma genotypes that may be uniquely responsive to Rapamycin. Based on its reported tolerability in dogs (alone and in combination with chemotherapy) it is reasonable to now ask if Rapamycin may improve treatment outcomes for dogs with hemangiosarcoma, and more precisely, to understand the hemangiosarcoma genotypes which may most benefit from its use.

Eligibility Criteria

• Dog that had a splenectomy performed within the previous 30 days and was found to have hemangiosarcoma based on histopathologic examination
• Dogs must weigh more than 5kg and less than 45kg

Interested?

Enroll or request more information below